Earnings summaries and quarterly performance for Coya Therapeutics.
Executive leadership at Coya Therapeutics.
Board of directors at Coya Therapeutics.
Research analysts covering Coya Therapeutics.
Recent press releases and 8-K filings for COYA.
Coya Therapeutics Announces $11.1 Million Private Placement
COYA
New Projects/Investments
- Coya Therapeutics, Inc. announced a private placement for the purchase and sale of 2,522,727 shares of its common stock at $4.40 per share.
- The offering is expected to generate gross proceeds of approximately $11.1 million.
- Key investors include Dr. Reddy's Laboratories, Inc. ($10 million) and Greenlight Capital ($1.1 million).
- The company intends to use the net proceeds to accelerate tech transfer and scale-up manufacturing activities for low dose IL-2 to support the commercial readiness of COYA 302.
- The closing of the offering is anticipated on or about January 30, 2026.
8 days ago
Coya Therapeutics Announces Private Placement
COYA
New Projects/Investments
- Coya Therapeutics has entered into a definitive securities purchase agreement for a private placement of 2,522,727 shares of its common stock at $4.40 per share, expected to generate approximately $11.1 million in gross proceeds.
- The investors in the offering are Dr. Reddy’s Laboratories, Inc., contributing $10 million, and Greenlight Capital, contributing $1.1 million.
- The company intends to use the net proceeds to accelerate tech transfer and scale-up manufacturing activities for low dose IL-2 to support the commercial readiness of COYA 302.
- The offering is expected to close on or about January 30, 2026.
8 days ago
Coya Therapeutics CEO Outlines 2026 Priorities and Financial Position
COYA
Guidance Update
New Projects/Investments
Strategic Partnerships
- Coya Therapeutics reported an unaudited cash balance of approximately $46.8 million as of December 31, 2025, with no debt, and a projected cash runway into the second half of 2027.
- The company is actively enrolling and dosing patients in its ALSTARS Phase 2 trial for ALS, targeting full enrollment in the second half of 2026 and a topline data readout in the first quarter of 2027.
- Coya plans to initiate a Phase 2a study for COYA 302 in Frontotemporal Dementia (FTD) in the second quarter of 2026, following FDA clearance and a $5 million investment from the Alzheimer's Drug Discovery Foundation.
- The company's scientific approach was validated by its Scientific Advisory Board member, Dr. Shimon Sakaguchi, receiving the 2025 Nobel Prize for his pioneering work in regulatory T-cell biology.
Jan 20, 2026, 1:00 PM
Coya Therapeutics Announces FDA Acceptance of IND for COYA 302 for FTD
COYA
New Projects/Investments
- Coya Therapeutics (NASDAQ: COYA) announced the U.S. FDA's acceptance of its Investigational New Drug (IND) application for COYA 302 for the treatment of Frontotemporal Dementia (FTD).
- FTD represents a high unmet medical need, affecting approximately 60,000 Americans with no current treatment to halt or improve disease progression.
- COYA 302 is an investigational biologic combination therapy designed to enhance regulatory T cell (Treg) function and suppress inflammation, and is also being developed for ALS and other neurodegenerative diseases.
- Coya expects to announce topline results in the coming weeks from an investigator-initiated open-label study evaluating low-dose IL-2 and CTLA4-Ig in mild-to-moderate FTD patients.
Jan 5, 2026, 1:00 PM
Coya Therapeutics Receives Health Canada Acceptance for ALS Clinical Trial
COYA
New Projects/Investments
- Health Canada has accepted Coya Therapeutics' Clinical Trial Application (CTA) for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).
- This acceptance allows for the initiation of patient enrollment in Canada for the ALSTARS Trial, which is a Phase 2, randomized, multi-center, double-blind, placebo-controlled study.
- The ALSTARS Trial is already underway in the United States, and the Canadian sites will enhance patient recruitment.
- COYA 302 is an investigational biologic combination therapy intended to enhance regulatory T cell function and suppress inflammation, and it is not yet approved by the FDA or any other regulatory agency.
Dec 23, 2025, 1:00 PM
Coya Therapeutics announces patient dosing in ALSTARS Trial for ALS and milestone payment
COYA
New Projects/Investments
- Coya Therapeutics has commenced dosing patients in its Phase 2 ALSTARS Trial of COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).
- COYA 302 is an investigational biologic combination therapy designed to enhance regulatory T cell function and suppress inflammation, and is not yet approved by regulatory agencies.
- As a result of this milestone, Coya will receive a $4.2 million milestone payment from its strategic partner, Dr. Reddy’s Laboratories.
Dec 9, 2025, 1:00 PM
Coya Therapeutics Reviews 2025 Accomplishments and Outlines 2026 Priorities
COYA
New Projects/Investments
Guidance Update
Product Launch
- Coya Therapeutics highlighted 2025 accomplishments, including its lead asset entering a Phase 2b/potentially registration trial, promising interim data from an investigator-initiated trial in frontotemporal dementia (FTD), and strong preclinical data for the combination of GLP-1s with COYA 301.
- The company's lead program, COYA 302, is currently in a randomized, double-blind, placebo-controlled Phase 2 study for ALS involving approximately 120 patients with a six-month primary endpoint of ALSFRS.
- Coya plans to initiate a Phase 2a study in FTD in the first half of 2026 and is advancing its GLP-1 COYA 303 program.
- The license agreement with Dr. Reddy's for ALS has a total deal value of approximately $700 million, with $16 million already received in milestone payments and upfronts, and an additional $4.2 million expected upon dosing the first patient.
- As of September 30, the company reported approximately $28 million in cash, and subsequently raised an additional $23 million in late October.
Dec 2, 2025, 1:45 PM
COYA Therapeutics CEO Discusses 2025 Accomplishments and 2026 Outlook
COYA
New Projects/Investments
Guidance Update
- COYA Therapeutics' lead asset, COYA 302, entered a Phase 2b potentially registration trial in 2025, marking a significant milestone.
- The company reported promising interim data from an investigator-initiated trial in frontotemporal dementia (FTD) and strong preclinical data on the synergistic potential of GLP-1s with COYA 301.
- COYA's Phase 2 study for ALS (COYA 302) is a randomized, double-blind, placebo-controlled trial with approximately 120 patients and a six-month primary endpoint using ALSFRS.
- Financially, COYA reported $28 million in cash as of September 30, 2025, and subsequently raised $23 million in late October 2025. An additional $4.2 million is expected from Dr. Reddy's upon dosing the first patient in December 2025, part of a $700 million total deal value for the ALS license agreement.
- Key objectives for 2026 include advancing the ALS trial, initiating an FTD trial, and progressing the GLP-1 COYA 303 program.
Dec 2, 2025, 1:45 PM
Coya Therapeutics discusses 2025 accomplishments and 2026 catalysts
COYA
New Projects/Investments
Guidance Update
- Coya Therapeutics' lead asset, COYA 302, has entered a Phase 2b potentially registration trial for ALS, with the primary endpoint being ALSFRS at six months. The company anticipates submitting the blinded data to the FDA after six months, which is expected to be sufficient for an approval pathway.
- The company expects to receive an additional $4.2 million from Dr. Reddy's upon dosing the first patient in the ALS trial, which is anticipated in December 2025. This is part of an approximately $700 million total deal value, from which Coya has already received $16 million in milestone payments and upfronts.
- As of September 30, 2025, Coya reported approximately $28 million in cash, and subsequently raised $23 million in late October 2025.
- Key priorities for 2026 include advancing the ALSTARS trial, initiating a Phase II-A study in frontotemporal dementia (FTD), and progressing the GLP-1 COYA 303 program.
Dec 2, 2025, 1:45 PM
Coya Therapeutics Investor Presentation Highlights Pipeline Progress and Financial Position
COYA
New Projects/Investments
Guidance Update
- Coya Therapeutics reported a cash balance of $28.1 million on September 30, 2025, and subsequently closed a $23 million gross proceeds underwritten public offering on October 27, 2025, projecting a cash runway into 2H 2027.
- The company's pipeline includes COYA-302, which received IND acceptance for a Phase 2 ALS trial with anticipated first patient dosing in 4Q 2025.
- Strategic partnerships include a potential ~$700 million deal value with Dr. Reddy's for COYA-302, with $4.2 million received in August 2025 and an additional $4.2 million anticipated in 4Q 2025.
- The Alzheimer's Drug Discovery Foundation (ADDF) invested $5 million to accelerate the Phase 2 trial of COYA-302 in Frontotemporal Dementia (FTD).
- In a Phase 2 study, COYA-301 in Alzheimer's Disease (AD) demonstrated cognition stabilization and significant improvement in Amyloid Beta Pathology for the lower IL-2 dose regimen.
Nov 30, 2025, 11:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more